Home - Invivoscribe

Skip to content

CATALOGS
NEWSROOM
CONTACT
CAREERS
LabPMM
MY ACCOUNT
CART

Search for:

PRODUCTS
- Next-Generation Sequencing
  CE-IVD
  Illumina®
  Thermo Fisher®
  RUO
  Illumina®
  Thermo Fisher®
  MRD
  LymphoTrack® Solutions
  LeukoStrat® FLT3-ITD MRD Assay
  LeukoStrat® NPM1 MRD Assay
- Companion Diagnostics (CDx)
  LeukoStrat® CDx FLT3 Mutation Assay
  CE-IVDR
  IVD (US)
  IVD (JP)
- ABI Fluorescence Detection
  CE-IVD
  Clonality
  FLT3
  RUO
  Clonality
  FLT3
  Translocations
- Gel Detection
  RUO
  Clonality
  FLT3
  Translocations
- Controls
  Master Mix Controls
  DNA Controls
  RNA Controls
  MRD Controls
- Software
  Dockerized
  LeukoStrat® FLT3-ITD MRD Software
  LeukoStrat® NPM1 MRD Software
  LymphoTrack® Enterprise Software – MiSeq™
  IdentiClone® RUO TCRG 2.0 Software
- Reagents
  ASRs
  Enzymes
  Hi-Di Formamide
- Product & Service Catalogs
CLINICAL LAB SERVICES
- Clinical Lab Services Overview
  
  The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.
  EXPLORE SERVICES ⟶
- Flow Cytometry
  Hematolymphoid Screening Panel
  AML MRD Assay
  CLL MRD Assay
- Companion Diagnostic (CDx) Tests
  CDx – USA
  CDx – Germany
  CDx – Japan
- NGS Cancer Panels
  MyAML
  MyMRD
- MRD NGS Tests
  Clonality
  FLT3 ITD
  NPM1
- Clonality NGS Tests
  SHM
  IGH
  IGK
  TRG
  TRB
DISEASES
- Lymphoid
  Mature B-cell
  Mature T-cell
  
  Lymphoma
  Lymphoma is a cancer that starts in cells that are part of the body’s immune system. Knowing which type of lymphoma you have is important because it affects your treatment options and your outlook (prognosis).
  
  LEARN MORE ⟶
- Myeloid
  Myelodysplastic Syndromes (MDS)
  Acute Myeloid Leukemia (AML)
  Myeloproliferative Neoplasms (MPNs)
  
  Myeloma
  Multiple myeloma is a cancer of plasma cells. Normal plasma cells are found in the bone marrow and are an important part of the immune system.
  
  LEARN MORE ⟶
- Hematological Testing Menu
  
  Browse our comprehensive menu of product & testing services.
  EXPLORE MENU ⟶
PARTNERSHIPS
- Partnerships Overview
  
  A proven strategy to accelerate drug approvals
  EXPLORE PARTNERSHIPS ⟶
- Product Development
  
  Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays
  EXPLORE ⟶
- Manufacturing
  
  cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents
  EXPLORE ⟶
- LabPMM®
  
  Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment
  EXPLORE ⟶
- Global Regulatory Expertise
  
  Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)
  EXPLORE ⟶
SCIENCE
- Science Overview
  
  We take pride in expanding the science that bridges personalized medicine with quality healthcare.
  EXPLORE OUR SCIENCE ⟶
- Personalized Medicine
  
  Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.
  EXPLORE PERSONALIZED MEDICINE ⟶
PUBLICATIONS
- Featured Publication
  
  November 17th, 2020
  Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing
  VIEW PUBLICATION ⟶
- Latest Publications
  
  April 20th, 2021
  Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing
  VIEW PUBLICATION ⟶
  
  November 17th, 2020
  Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing
  VIEW PUBLICATION ⟶
  
  VIEW ALL PUBLICATIONS ⟶
COMPANY
- Company
  About Us
  Leadership Team
  Board of Directors
  Global Distributors
  Licensure and Certifications
  Search Career Openings
- Invivoscribe Locations
  
  Invivoscribe, Inc. (USA)
  
  San Diego, CA, US
  
  CONTACT US ⟶
  
  Invivoscribe, SARL (France)
  
  Marseille, France
  
  CONTACT US ⟶
  
  Invivoscribe Diagnostic Technologies,(Shanghai) Co.,Ltd.
  
  Shanghai, China
  
  CONTACT US ⟶
- Clinical Lab Locations
  
  LabPMM, LLC (USA)
  
  San Diego, CA, US
  
  CONTACT US ⟶
  
  LabPMM, GmbH (Germany)
  
  Munich, Germany
  
  CONTACT US ⟶
  
  LabPMM, GK (Japan)
  
  Kawasaki, Japan
  
  CONTACT US ⟶
  
  Invivoscribe Diagnostic Technologies,(Shanghai) Co.,Ltd.
  
  Shanghai, China
  
  CONTACT US ⟶
- Support
  
  Invivoscribe, Inc. (USA)
  
  CONTACT US ⟶
  
  Invivoscribe, SARL (France)
  
  CONTACT US ⟶
  
  Invivoscribe Diagnostic Technologies,(Shanghai) Co.,Ltd.
  
  CONTACT US ⟶
  
  LabPMM, LLC (USA)
  
  CONTACT US ⟶
  
  LabPMM, GmbH (Germany)
  
  CONTACT US ⟶
  
  LabPMM, GK (Japan)
  
  CONTACT US ⟶

SEARCH & FILTER

Territory
- AUS
- European Economic Area
- Global
- Mexico and Canada
- Outside North America
- Outside US and EU
- US
- Worldwide
Detection
- ABI
- ASR – Undefined
- Capillary Electrophoresis
- Gel
- Ion PGM™
- Ion S5™
- MiSeq™
- NGS
Regulatory Classification
- Analyte Specific Reagent (ASR)
- CAP/CLIA
- CAP/CLIA-validated
- CAP/CLIA-validated LDT
- CE-2797
- CE-2797 IVD
- CE-marked IVD
- Companion Diagnostic
- DAkkS, RiliBAK
- General Purpose Reagent (GPR)
- IVD
- Research Use Only (RUO)
- RUO
- SHM
- To Be Determined
Locus Target
- B-Cell
- BCL2-IGH
- BCR-ABL1
- CBFB-MYH11 inv(16)
- Companion Diagnostics
- E2A-PBX1
- FLT3
- FLT3 ITD
- FLT3 ITD MRD Assay
- FLT3 ITD Signal Ratio
- FLT3 TKD
- IGH
- IGH-BCL 1
- IGH-BCL1
- IGH-BCL2
- IGH-CCND1 (BCL1)
- IGK
- IGL
- ITD
- KMT2A
- Leader
- Negative
- NPM1
- PML-RARα
- SHM
- T-Cell
- TRB
- TRD
- TRG
Application
- Biomarker Panel
- Clonality
- Coronavirus
- DNA Quality Control
- Gene Panel
- MRD
- Mutation
- Proficiency
- Screening
- Sensitivity
- Somatic Hypermutation
- Translocation
Product Type
- Assay Kit
- DNA Control
- DNA Sensitivity Panel
- Master Mix
- MRD Control
- Reagent
- Regular Kit (30 Reactions)
- RNA Control
- RNA Dilution Set
- RNA Sensitivity Panel
- Service
- Software
Box Type
- 1-CD
- 1-tube
- 10-tubes
- 100-place box
- 12-place box
- 30-place box
- 6-tubes
- 7-tubes
- IVDR IdentiClone Dx
- LeukoStrat CDx FLT3 Box
Design
- BIOMED
- BIOMED-2
- Genection
- Invivoscribe
- LabPMM
Size
- 1 CD
- 1 Software Package
- 1 Unit
- 1 USB
- 1 x 100 uL
- 1 x 1000 uL
- 1 x 1000 µL
- 1 x 1500 uL
- 1 x 1500 µL
- 1 x 1800 µL
- 1 x 200 µL
- 1 x 250 µL
- 1 x 45 uL
- 1 x 50 µL
- 10 x 100 uL
- 1000 µL
- 12 indices per FR region – 5 reactions each
- 12-index Kit (60 reactions)
- 24 indices per FR region – 5 reactions each
- 24-index Kit (120 reactions)
- 24-index Kit (96 reactions)
- 32 Reactions
- 6 x 100 uL
- 6 x 50 uL
- 6 x 50 µL
- 7 x 100 uL
- 8 indices per FR region – 5 reactions each
- 8-index Kit (40 reactions)
- 96 reactions
- MegaKit (300 Reactions)
- MegaKit (300/330 reactions)
- MegaKit (330 reactions)
- Regular Kit (30 Reactions)
- Regular Kit (30/33 reactions)
- Regular Kit (33 reactions)
- Unit
Reset Filter

SEARCH & FILTER
- Filter Products

HomeMarketing2021-08-30T03:01:12+00:00

Invivoscribe-Shop-FS-1920×275-Background-Image-001

Products & Clinical Lab Services

Invivoscribe

PRODUCTS & CLINICAL LAB SERVICES

Cat #: IGH Clonality
IGH Clonality Assays
Lymphoid cells are different from the other somatic cells in the body as during development, the antigen receptor genes of these cells undergo somatic...
View Product
Cat #: A1010041
IGH DH1-6 – HEX
This product targets the diversity and joining regions of the human immunoglobulin heavy chain gene. ...
View Product
Cat #: A1010051
IGH DH7 – 6FAM
This product targets the diversity and joining regions of the human immunoglobulin heavy chain gene. ...
View Product
Cat #: A1010011
IGH FR1- 6FAM
This product targets the framework 1 region of the human immunoglobulin heavy chain gene. ...
View Product
Cat #: A1010101
IGH FR2 – 6FAM
This product targets the framework 2 region of the human immunoglobulin heavy chain gene. ...
View Product
Cat #: A1010031
IGH FR3 – HEX
This product targets the framework 3 region of the human immunoglobulin heavy chain gene. ...
View Product
Cat #: A1010061
IGH Framework 1 – 6FAM
This product targets the framework 1 region of the human immunoglobulin heavy chain gene. ...
View Product
Cat #: A1010091
IGH Framework 2 – 6FAM
This product targets the framework 2 region of the human immunoglobulin heavy chain gene. ...
View Product
Cat #: A1010081
IGH Framework 3 – HEX
This product targets the framework 3 region of the human immunoglobulin heavy chain gene. ...
View Product
Cat #: 11010061
IGH Gene Clonality Assay for ABI Fluorescence Detection
BACKGROUND: Rearrangements of the antigen receptor genes occur during ontogeny in B and T lymphocytes. These gene rearrangements generate products t...
View Product
Cat #: 11010020
IGH Gene Clonality Assay for Gel Detection
BACKGROUND: Rearrangements of the antigen receptor genes occur during ontogeny in B and T lymphocytes. These gene rearrangements generate products t...
View Product
Cat #: 11010081
IGH Gene Clonality Assay MegaKit for ABI Fluorescence Detection
BACKGROUND: Rearrangements of the antigen receptor genes occur during ontogeny in B and T lymphocytes. These gene rearrangements generate products t...
View Product
Cat #: 11010051
IGH Gene Rearrangement Assay for ABI Fluorescence Detection
BACKGROUND: Rearrangements of the antigen receptor genes occur during ontogeny in B and T lymphocytes. These gene rearrangements generate products t...
View Product
Cat #: 11010071
IGH Gene Rearrangement Assay MegaKit for ABI Fluorescence Detection
BACKGROUND: Rearrangements of the antigen receptor genes occur during ontogeny in B and T lymphocytes. These gene rearrangements generate products t...
View Product
Cat #: 40880008
IGH SHM Positive Control DNA
This DNA control is adjusted to a final concentration of 15 µg/mL in 1/10 TE (1mM Tris-HCl (pH 8.0), 0.1 mM EDTA). This diluent provides sufficient b...
View Product
Cat #: IGH-Somatic-Hypermutation-Assay
IGH Somatic Hypermutation Assay
Lymphoid cells are different from the other somatic cells in the body as during development, the antigen receptor genes in these cells undergo somatic...
View Product
Cat #: 51010041
IGH Somatic Hypermutation Assay MegaKit v2.0 for ABI Fluorescence Detection
BACKGROUND Rearrangements of the antigen receptor genes occur during ontogeny in B and T lymphocytes. These gene rearrangements are unique in length...
View Product
Cat #: 51010040
IGH Somatic Hypermutation Assay MegaKit v2.0 for Gel Detection
BACKGROUND Rearrangements of the antigen receptor genes occur during ontogeny in B and T lymphocytes. These gene rearrangements are unique in length...
View Product
Cat #: 51010031
IGH Somatic Hypermutation Assay v2.0 for ABI Fluorescence Detection
BACKGROUND Rearrangements of the antigen receptor genes occur during ontogeny in B and T lymphocytes. These gene rearrangements are unique in length...
View Product
Cat #: 51010030
IGH Somatic Hypermutation Assay v2.0 for Gel Detection
BACKGROUND Rearrangements of the antigen receptor genes occur during ontogeny in B and T lymphocytes. These gene rearrangements are unique in length...
View Product

Previous
1
2
3
4
5
6
7
...
11
12
Next

Now Available

Our New Document Search Feature

Need Help Placing an Online Order?

Contact our Customer Service Team

CONTACT CUSTOMER SERVICE ⟶

Now Available

Our New Document Search Feature

Need Help Placing an Online Order?

Contact our Customer Service Team

CONTACT CUSTOMER SERVICE ⟶

INVIVOSCRIBE

Invivoscribe, Inc. (USA)

San Diego, CA, US

Invivoscribe, SARL (France)

Marseille, France

Invivoscribe Diagnostic Technologies, (Shanghai) Co., Ltd.

Shanghai, China

CLINICAL LAB LOCATIONS

LabPMM, LLC (USA)

San Diego, CA, US

LabPMM, GmbH (Germany)

Munich, Germany

LabPMM, GK (Japan)

Kawasaki, Japan

Invivoscribe Diagnostic Technologies, (Shanghai) Co., Ltd.

Shanghai, China

PRIVACY/TERMS & CONDITIONS

Terms and Conditions
Privacy Policy
Web Privacy Policy
Cookie Policy
Licensure and Certifications
Global Distributors
Genection

CONNECT

© 2018 - | Invivoscribe, Inc. | All Rights Reserved

End User License Agreement

CAREFULLY READ THE TERMS OF THIS END USER LICENSE AGREEMENT BETWEEN YOU AND INVIVOSCRIBE, INC., A CALIFORNIA CORPORATION (“LICENSOR”) BEFORE ACCESSING OR USING Invivoscribe Software (THE “PRODUCT”). BY ACCESSING OR USING THE PRODUCT, OR CLICKING BELOW TO ACKNOWLEDGE YOUR ACCEPTANCE OF THE TERMS AND CONDITIONS OF THIS AGREEMENT, YOU, AS THE USER OF THE PRODUCT, IN WHATEVER CAPACITY (EACH AN “AUTHORIZED USER”), AGREE TO THE TERMS OF THIS AGREEMENT. IF YOU DO NOT AGREE TO ALL OF THE TERMS OF THIS AGREEMENT, DO NOT ACCESS OR USE THE PRODUCT, OR CLICK BELOW TO ACKNOWLEDGE YOUR ACCEPTANCE OF THE TERMS AND CONDITIONS OF THIS AGREEMENT. BY USING THE PRODUCT, YOU ASSERT THAT YOU ARE AN AUTHORIZED REPRESENTATIVE OF THE END USER WITH AUTHORITY TO ENTER INTO THIS AGREEMENT.

This End User License Agreement (“Agreement”) is made and entered into by and between INVIVOSCRIBE, INC., a California corporation (“Licensor”) and You (either an individual or a legal entity), the “Licensee,” as defined herein for the licensing and usage of the Licensor’s software. Licensee acknowledges and agrees that Licensee’s right to use the software in any manner shall be controlled by this Agreement and that such use shall be strictly in accordance with the terms and conditions of this Agreement.

GRANT OF LICENSE. Licensor grants to Licensee a non-exclusive, non-transferable, limited license, without right to sublicense, to use the software and any accompanying written materials and any documents or other content embodying information contained within the software (collectively, the “Product”) only for Licensee’s own use. Except as agreed in a document signed by Licensor, the software license granted in the preceding sentence is limited to use with Licensor’s Assays purchased from Licensor or from an authorized distributor of Licensor. Licensor reserves all rights not expressly granted to Licensee. The limited license granted by this Agreement and Licensee’s payment of the license fee, if any, give Licensee the right to use the Product only in accordance with the terms of this Agreement. This license is not a sale of the original software or any copy.
CONFIDENTIALITY. Licensee agrees that the Product is based on and includes the intellectual property, including proprietary trade secrets, inventions, copyrights, patent applications, and/or granted patents (“Intellectual Property”) of Licensor, and that Licensor owns all such Intellectual Property. Possession and use of the Product shall be strictly in accordance with this Agreement, and receipt or possession does not convey to Licensee any rights in the Product or the Intellectual Property, or any rights to divulge, reproduce, or allow others to use the Product outside the terms of this Agreement without specific written authorization of Licensor. Licensee agrees not to disclose, copy, publish, translate, release, or distribute copies of the Product or any portion thereof to others outside the terms of this Agreement. Licensee may not modify, adapt, translate, reverse engineer, decompile, disassemble, or create derivative works based on any portion of the Product, including any documents or other content produced using the software.
OWNERSHIP OF PRODUCT. Title to, ownership of, and all rights and interests in the Product, all copies thereof, and any Intellectual Property relating thereto, remains at all times vested in Licensor.
COPY RESTRICTIONS. The Product is copyrighted. Unauthorized copying or modification of the Product, including software that has been modified, merged, or included with other software, is expressly forbidden. Licensee may be held legally responsible for any copyright infringement that is caused or incurred by Licensee’s failure to abide by the terms of this Agreement.
TRANSFER RESTRICTIONS. This Product is licensed to Licensee, and may not be transferred to anyone without the prior written consent of Licensor. In no event may Licensee transfer, assign, rent, lease, sell, or otherwise dispose of the Product, or any portion thereof, except as expressly provided herein.
TERMINATION. This Agreement will be terminated automatically without notice if Licensee fails to comply with any provision of this Agreement.
LIMITED WARRANTY. THE PRODUCT AND ANY ACCOMPANYING WRITTEN MATERIALS, INCLUDING INSTRUCTIONS FOR USE, ARE PROVIDED “AS IS,” WITHOUT WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. LICENSEE BEARS THE ENTIRE RISK OF THE QUALITY AND PERFORMANCE OF THE PRODUCT. FURTHER, LICENSOR DOES NOT WARRANT THE RESULTS OF USE OF THE PRODUCT OR THAT THE PRODUCT IS BUG/ERROR FREE OR THAT ITS USE WILL BE UNINTERRUPTED. THIS DISCLAIMER OF WARRANTY CONSTITUTES AN ESSENTIAL PART OF THIS AGREEMENT. BECAUSE SOME STATES OR JURISDICTIONS DO NOT ALLOW LIMITATIONS ON HOW LONG AN IMPLIED WARRANTY LASTS, THE ABOVE LIMITATION MAY NOT APPLY.
LIMITED LIABILITY. IN NO EVENT SHALL LICENSOR BE LIABLE FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, OR INCIDENTAL OR PUNITIVE DAMAGES, INCLUDING DAMAGES FOR LOSS OF PROFITS, LOSS OR DAMAGE OF DATA, BUSINESS INTERRUPTION, OR LOSS OF GOODWILL, AND THE LIKE, ARISING OUT OF THE USE OF OR INABILITY TO USE THE PRODUCT, EVEN IF LICENSOR HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. IN NO EVENT SHALL ANY PARTY’S LIABILITY TO THE OTHER, WHETHER IN CONTRACT, TORT (INCLUDING NEGLIGENCE), BREACH OF WARRANTY, OR OTHERWISE, EXCEED THE LICENSE FEES RECEIVED BY LICENSOR FROM LICENSEE IN THE TWELVE (12) MONTH PERIOD PRIOR TO THE CLAIM, WHETHER ANY REMEDY SET FORTH HEREIN FAILS OF ITS ESSENTIAL PURPOSE OR OTHERWISE. BECAUSE SOME STATES OR JURISDICTIONS DO NOT ALLOW LIMITATION OR EXCLUSION OF CONSEQUENTIAL OR INCIDENTAL DAMAGES, THE ABOVE LIMITATION MAY NOT APPLY TO LICENSEE. Licensee agrees that the limitations of liability and disclaimers set forth herein will apply regardless of whether Licensee has accepted the Product.
GOVERNING LAW. This Agreement shall be governed by the laws of the State of California, irrespective of its conflicts of laws provisions, and Licensee consents to jurisdiction by the state and federal courts sitting in San Diego County California.
COMPLETE AGREEMENT. This Agreement is the entire agreement between Licensor and Licensee with respect to the Product and the subject matter set forth herein. This Agreement replaces all prior understandings and agreements, whether written or oral, between Licensee and Licensor regarding the Product. This Agreement may not be modified unless Licensor and Licensee both agree to such modificatoin in writing.
SEVERABILITY. If for any reason a court of competent jurisdiction finds any provision or part of any provision of this Agreement unenforceable or contrary to law, such provision or part will be changed and interpreted so as to best accomplish the objectives of the original provision to the fullest extent allowed by law and the remaining provisions of the Agreement shall continue in full force and effect.
EQUITABLE RELIEF. The parties agree that a material breach of this Agreement adversely affecting Licensor’s intellectual property rights in Product may cause irreparable injury to Licensor for which monetary damages would not be an adequate remedy and the non-breaching party shall be entitled to equitable relief (without a requirement to post a bond) in addition to any remedies it may have hereunder or at law.
LEGAL FEES. In any action to enforce one’s rights hereunder, the non-prevailing party shall pay the reasonable fees and expenses of the prevailing party.
ARBITRATION. Any dispute arising out of or relating to this Agreement shall be settled by binding arbitration in accordance with the commercial rules of JAMS (formerly the Judicial Arbitration and Mediation Services) by one arbitrator. Each party shall select one arbitrator, and such two arbitrators shall select a third independent arbitrator, which third arbitrator shall be the sole arbitrator in the matters. Selection of arbitrators shall be made within 30 days after the date of the first notice of demand for arbitration. The results of such arbitration proceedings shall be binding upon the parties hereto, and judgment may entered upon the arbitration award in any court having jurisdiction thereof. The cost of each arbitration proceeding shall be borne equally by the parties. The parties shall pay all of their own expenses of the arbitration, including but not limited to legal fees and costs. The arbitrator shall also award the party that prevails substantially in the arbitration its reasonable attorneys’ fees and costs incurred in connection with the arbitration. All arbitration proceedings shall be held in San Diego, California unless the parties agree otherwise. The arbitrator is empowered to render an award of general compensatory damages and equitable relief (including, without limitation, injunctive relief), but is not empowered to award punitive or presumptive damages. The parties hereto will maintain the substance of any proceedings hereunder in confidence and make disclosures to others only to the extent necessary to properly conduct the proceedings or as otherwise required by law. The parties shall instruct the arbitrator to render his/her decision no later than thirty (30) days after the submission of the dispute. Notwithstanding the foregoing, either party may seek interim injunctive relief from any court of competent jurisdiction.
ASSIGNMENT. This Agreement is non-assignable unless the other party consents, which consent shall not be unreasonably withheld. Either party may assign this Agreement, without the consent of the other party, to a successor in interest in the event of a merger, acquisition or re-organization. Any action or conduct in violation of the foregoing shall be void and without effect.

©2022 Invivoscribe, Inc. All rights reserved. The trademarks mentioned herein are the property of Invivoscribe, Inc. and/or its affiliates, or (as to the trademarks of others used herein) their respective owners.

PRODUCTS
CLINICAL LAB SERVICES
DISEASES
PARTNERSHIPS
SCIENCE
- Science Overview
- Personalized Medicine
PUBLICATIONS
- Featured Publication
- Latest Publications
NEWSROOM
COMPANY

LATEST NEWS
Invivoscribe Announces Key Submission in the EU ⟶

CONNECT